PeptideStack
5.2kquestions
20kanswers
220users

Would you re-test ecnoglutide after four weeks at 25 °C, or accept the original certificate?

Asked 18 Jul 2026Modified 1 min agoViewed 6.6k times
16

Conditions: ecnoglutide · four weeks · 25 °C.

The failure mode I am trying to avoid is making this decision emotionally.

I have twelve months in view and I would like the plan to survive that long.

What would you do, and what would make you change course?

batch-testing
batch-testing

Testing at the batch or lot level: sampling plans, how many vials from a lot need testing to say anything about the lot, and the difference…

910 questions
peptide-stability
peptide-stability

The chemistry of peptide degradation: deamidation, oxidation, hydrolysis, aggregation and fibrillation, and how temperature, pH, ionic strength,…

908 questions
coa
coa

Certificates of analysis: what fields a useful one carries, how to tell a real analytical report from a marketing document, batch and lot…

771 questions
ecnoglutide
ecnoglutide

A long-acting GLP-1 receptor agonist with a cAMP-biased signalling profile. A niche tag, mostly used for mechanism questions about biased agonism…

223 questions
shareeditfollowflag
MH
askedm_haraldsen21k2718 Jul 2026
6Is the comparison against a supplier certificate or against a second independent result? – sian_llewellyn 8 months ago
5Voting to keep this open — it is more specific than it first looks. – assay_blank 6 months ago
add a comment

5 Answers

Accepted answer first, then by votes
5

Accepted answer

four weeks is 28 days, and at 25 °C the ten-degree rule of thumb makes that roughly 112 refrigerated days of equivalent exposure. 25 °C is 20 kelvin above the 5 °C middle of a 2–8 °C refrigerator. The ten-degree rule of thumb — degradation rate roughly doubling per 10 K — makes that about 4 times the refrigerated rate, which is an order-of-magnitude statement and not a shelf life. Compare that against what the certificate covers, which is the material as it left the laboratory on the date of analysis and nothing after it. That is short enough that a re-test is a stability study rather than a safety check — worth doing if you will publish the result, hard to justify if you will only reassure yourself. If you do re-test, send it for content as well as purity; the 28 days will have moved one of them further than the other.

Sampling plans exist precisely because testing everything is expensive, and they define the statistical relationship between sample size and lot-wide inference.

Under AQL sampling plans, testing two vials from a fifty-vial lot gives you an operating characteristic curve that tells you what risks you are accepting.

Mass shifts and what they usually mean

Δ mass (Da)Most likely causeDistinguishing feature
+1Deamidation (Asn or Gln)New peak, slightly earlier retention
−17Loss of ammoniaOften with deamidation
−18Dehydration / succinimidepH-dependent, reversible
+16Oxidation (Met, Trp)Earlier retention, light-related
−128Missing Gln or LysDeletion sequence from synthesis
0Isomer: racemisation or scramblingSame mass, shifted retention

Mechanically, if the lot was manufactured in multiple batches, testing vials from each batch separately establishes whether batch-to-batch variation is acceptable.

Lyophilised peptide homogeneity studies show that vial-to-vial variation is usually small but occasionally large, depending on the distribution in the freeze-dryer.

Assume segregation is possible, and design your sampling to catch it if it exists.

shareimprove this answerflag
CO
answered · acceptedcoldbox941k13819 Jul 2026
Sponsored

Sigma-Aldrich - Certified Reference Materials

Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.

Shop standards
5

The failure mode here is publishing a result that applies to the tested vial alone while implying it applies to the entire lot.

The statistical foundation here is well-established, which is why sampling plans from decades ago are still valid.

Stated carefully, published segregation failures show that even modern automated processes sometimes produce lots with measurable vial-to-vial variation.

One qualification: testing more vials gives better confidence, but at some point the cost outweighs the benefit.

The practical summary: a lot number without a sampling statement is a lot number without meaning.

shareimprove this answerflag
HP
answeredh_pergande71k15829 Jul 2026
8Adding for future readers: the certificate should carry the lot number, not just a batch code. – Dr_Bram_Verhoeven 2 months ago
The system-suitability data is the part that tells you whether to believe the rest. – two_point_four 4 months ago
add a comment
2

The practical consequence is that spot-testing one vial from a new supplier is better than assuming they are all the same.

If you have reason to suspect inhomogeneity — different appearance in different vials, or a long or warm shipment — testing more vials is the diagnostic move.

Acceptance Sampling by Attributes defines the number of samples you need from a lot to claim a specified quality level at a specified risk — it is in ANSI standard Z1.4.

Sampling plans for pharmaceutical manufacturing are defined in ISO 2859 and ANSI Z1.4, and they are based on statistical sampling theory.

Worth noting that thermal excursions during shipping affect different vials differently, so the lot may not be homogeneous even if it left the factory that way.

If testing multiple vials, state how many you tested and why you chose those vials.

shareimprove this answerflag
P9
answeredplate_count_9k78k24829 Jul 2026
Thank you — this is the answer I was looking for. – jana_horakova 31 days ago
add a comment
1

Start from the question: how many vials from this lot do I need to test to claim that the lot meets specification, and the answer depends on both the lot size and the acceptable risk.

The sample size determination requires choosing a confidence level and an acceptable error rate, and the smaller the error rate you want, the larger your sample must be.

Published data on lot homogeneity from manufacturers who sample multiple vials consistently find variation below the published specifications, suggesting the sampling plans work.

If you only pay for one test, pay for quantified content. Purity is the number everyone quotes and content is the number that changes what you do.

shareimprove this answerflag
DV
answeredDr_Ilse_Vandenberg113k24826 Jul 2026
1

The single most misleading statement on a research-grade certificate is a lot number with no statement of how many vials from that lot were tested.

A statement that "lot 20260412 complies with specifications" is meaningless without stating which vials from the lot were tested and how many there were.

The ICH Q3A and Q3B thresholds for reporting, identification and qualification of impurities are the framework the pharmaceutical industry works to, and they are worth reading even though nothing in the research-grade supply chain is obliged to meet them, because they tell you which numbers a competent analyst would consider worth reporting at all.

In practice: ask for the chromatogram, check the method section, check the lot number against the vial, and set your accept threshold before you see the result rather than after.

edited 19 Aug 2026 by kwn_analytical — tightened the wording; no substantive change

shareimprove this answerflag
KA
answeredkwn_analytical147k35830 Jul 2026

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.